Phase II trial of echinomycin in advance
β
Sarah A. Taylor; Barbara Metch; Stanley P. Balcerzak; Karl H. Hanson
π
Article
π
1990
π
Springer US
π
English
β 232 KB
Thirty-four patients with advanced soft tissue sarcomas were entered in a phase II trial of echinomycin. Patients received 1.2 mg/m 2 intravenously (i.v.) weekly times four followed by a two week rest period. There were no objective responses. Dose limiting toxicity was gastrointestinal. Echinomycin